Stockscreener 앱 받기
17.00
8.01%
-1.48
Maplight Therapeutics Inc 주식(MPLT)의 최신 뉴스
Biopharma financings pick up in Q4 to cap uneven 2025 recovery - BioWorld MedTech
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Down 7.7%Here's Why - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Stock Price Up 10.5%Time to Buy? - MarketBeat
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of “Buy” from Brokerages - Defense World
Maplight Therapeutics, Inc. (NASDAQ:MPLT) Receives Average Recommendation of "Buy" from Brokerages - MarketBeat
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap UpHere's What Happened - MarketBeat
MapLight Therapeutics stock rises after accelerating clinical trial timelines By Investing.com - Investing.com Nigeria
MapLight Therapeutics stock rises after accelerating clinical trial timelines - Investing.com
MapLight Therapeutics accelerates timeline for Phase 2 trial results By Investing.com - Investing.com Nigeria
MapLight updates trial timelines and highlights CNS pipeline - TipRanks
MapLight Therapeutics accelerates timeline for Phase 2 trial results - Investing.com
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - The Manila Times
MapLight Therapeutics Updates Expected Timing of Topline Results for Ongoing Phase 2 Studies to Q3 2026 - GlobeNewswire Inc.
FDA grants fast track designation to MapLight’s Alzheimer’s drug By Investing.com - Investing.com Nigeria
Maplight Therapeutics (MPLT) FDA Approvals, PDUFA Dates & Drug Alerts 2026 - MarketBeat
MapLight Therapeutics' Alzheimer's Psychosis Drug Granted FDA Fast Track Status - Nasdaq
MapLight Therapeutics Receives Fast Track Designation for ML-007C-MA for Alzheimer’s Disease Psychosis - The Manila Times
Maplight Therapeutics (NASDAQ:MPLT) Shares Down 7.9%Should You Sell? - MarketBeat
MapLight’s phase 2 Alzheimer’s psychosis trial marks a key milestone for MPLT investors - MSN
What is the current Price Target and Forecast for MapLight Therapeutics, Inc. (MPLT) - Zacks Investment Research
MapLight’s Phase 2 Alzheimer’s Psychosis Trial Marks a Key Milestone for MPLT Investors - TipRanks
MapLight Therapeutics Earnings Notes - Trefis
MapLight Therapeutics advances CNS drug pipeline - MSN
MapLight’s ML-004 Autism Extension Study: What Ongoing Safety Data Mean for Investors - TipRanks
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to S&P TMI Index - marketscreener.com
Aktis Oncology files for US IPO as biotech listings rebound - whbl.com
Maplight Therapeutics (NASDAQ:MPLT) Upgraded by Wall Street Zen to Hold Rating - Defense World
MapLight2025 Funding Rounds & List of Investors - Tracxn
MapLight Therapeutics, Inc.(NasdaqGS: MPLT) added to Russell 2000 Growth Index - marketscreener.com
Maplight Therapeutics (NASDAQ:MPLT) Shares Gap DownHere's What Happened - MarketBeat
SandboxAQ and MapLight join forces on CNS - The Pharma Letter
6 Biotechs That Could Be Big Pharma’s Next M&A Target - BioSpace
SandboxAQ and MapLight Therapeutics Partner on Novel CNS Therapies - HPCwire
SandboxAQ and MapLight form $200 million CNS drug discovery alliance By Investing.com - Investing.com Nigeria
SandboxAQ and MapLight form $200 million CNS drug discovery alliance - Investing.com
MapLight links up with SandboxAQ to pursue AI-discovered CNS treatments - Axios
SandboxAQ and MapLight Therapeutics Announce Strategic Collaboration to Discover and Develop Novel CNS Therapies - The Manila Times
Sandboxaq And Maplight Therapeutics Announce Collaboration To Discover And Develop Novel CNS Therapies - TradingView — Track All Markets
MapLight Therapeutics to join Russell 3000, Russell 2000 and Russell Microcap indexes - MSN
Potential Bristol Myers rival MapLight seeks $250M in U.S. IPO - MSN
MapLight Therapeutics completes IPO and raises $296.5M - MSN
Analysts Offer Insights on Healthcare Companies: MapLight Therapeutics, Inc. (MPLT) and Halozyme (HALO) - The Globe and Mail
Maplight Therapeutics (MPLT) Stock Trends and Sentiment 2025 - MarketBeat
symbol__ Stock Quote Price and Forecast - CNN
Adversity is less terrifying than hope: MapLight Therapeutics Inc (MPLT) - setenews.com
4.73%
0.92%
자본화:
|
볼륨(24시간):